|
1
|
Byström J, Garcia RC, Håkansson L, et al:
Eosinophil cationic protein is stored in, but not produced by,
peripheral blood neutrophils. Clin Exp Allergy. 32:1082–1091. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carreras E, Boix E, Navarro S, Rosenberg
HF, Cuchillo CM and Nogues MV: Surface-exposed amino acids of
eosinophil cationic protein play a critical role in the inhibition
of mammalian cell proliferation. Mol Cell Biochem. 272:1–7. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molin D: Bystander cells and prognosis in
Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci.
109:179–228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Navarro S, Aleu J, Jiménez M, Boix E,
Cuchillo CM and Nogués MV: The cytotoxicity of eosinophil cationic
protein/ribonuclease 3 on eukaryotic cell lines takes place through
its aggregation on the cell membrane. Cell Mol Life Sci.
65:324–337. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Venge P and Byström J: Eosinophil cationic
protein (ECP). Int J Biochem Cell Biol. 30:433–437. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Venge P, Byström J, Carlson M, et al:
Eosinophil cationic protein (ECP): molecular and biological
properties and the use of ECP as a marker of eosinophil activation
in disease. Clin Exp Allergy. 29:1172–1186. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang J and Rosenberg HF: Sequence
variation at two eosinophil-associated ribonuclease loci in humans.
Genetics. 156:1949–1958. 2000.PubMed/NCBI
|
|
8
|
Eriksson J, Woschnagg C, Fernvik E and
Venge P: A SELDI-TOF MS study of the genetic and post-translational
molecular heterogeneity of eosinophil cationic protein. J Leukoc
Biol. 82:1491–1500. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eriksson J, Reimert CM, Kabatereine NB, et
al: The 434 (G>C) polymorphism within the coding sequence of
eosinophil cationic protein (ECP) correlates with the natural
course of Schistosoma mansoni infection. Int J Parasitol.
37:1359–1366. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jönsson UB, Byström J, Stålenheim G and
Venge P: Polymorphism of the eosinophil cationic protein-gene is
related to the expression of allergic symptoms. Clin Exp Allergy.
32:1092–1095. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koh GCH, Shek LPC, Goh DYT, Van Bever H
and Koh DSQ: Eosinophil cationic protein: Is it useful in asthma? A
systematic review. Respira Med. 101:696–705. 2007. View Article : Google Scholar
|
|
12
|
Trulson A, Byström J, Engstrom A, Larsson
R and Venge P: The functional heterogeneity of eosinophil cationic
protein is determined by a gene polymorphism and post-translational
modifications. Clin Exp Allergy. 37:208–218. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Byström J, Tenno T, Håkansson L, et al:
Monocytes, but not macrophages, produce the eosinophil cationic
protein. APMIS. 109:507–516. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sugihara R, Kumamoto T, Ito T, Ueyama H,
Toyoshima I and Tsuda T: Human muscle protein degradation in vitro
by eosinophil cationic protein (ECP). Muscle Nerve. 24:1627–1634.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Young JD, Peterson CGB, Venge P and Cohn
ZA: Mechanism of membrane damage mediated by human eosinophil
cationic protein. Nature. 321:613–616. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carreras E, Boix E, Rosenberg HF, Cuchillo
CM and Nogués MV: Both aromatic and cationic residues contribute to
the membrane-lytic and bactericidal activity of eosinophil cationic
protein. Biochemistry. 42:6636–6644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cormier SA, Taranova AG, Bedient C, et al:
Pivotal advance: Eosinophil infiltration of solid tumors is an
early and persistent inflammatory host response. J Leukoc Biol.
79:1131–1139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mingomataj EC: Eosinophil-induced
prognosis improvement of solid tumors could be enabled by their
vesicle-mediated barrier permeability induction. Med Hypotheses.
70:582–584. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Munitz A and Levi-Schaffer F: Eosinophils:
‘new’ roles for ‘old’ cells. Allergy. 59:268–275. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samoszuk M: Eosinophils and human cancer.
Histol Histopathol. 12:807–812. 1997.PubMed/NCBI
|
|
21
|
Simson L, Ellyard JI, Dent LA, et al:
Regulation of carcinogenesis by IL-5 and CC111: a potential role
for eosinophils in tumor immune surveillance. J Immunol.
178:4222–4229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trulson A, Nilsson S and Venge P: The
eosinophil granule proteins in serum, but not the oxidative
metabolism of the blood eosinophils, are increased in cancer. Br J
Haematol. 98:312–314. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Agostini M, Silva SD, Zecchina KG, et al:
Fatty acid synthase is required for the proliferation of human oral
squamous carcinoma cells. Oral Oncol. 40:728–735. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gomes CC, Moreira LM, Santos VJSV, et al:
Assessment of the genetic risks of a metallic alloy used in medical
implants. Genet Mol Biol. 34:116–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lorena SC, Oliveira DT, Dorta RG, Landman
G and Kowalski LP: Eotaxin expression in oral squamous cell
carcinomas with and without tumour associated tissue eosinophilia.
Oral Dis. 9:279–283. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ellyard JI, Simson L and Parish CR:
Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens.
70:1–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murdoch C, Muthana M, Coffelt SB and Lewis
CE: The role of myeloid cells in the promotion of tumour
angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trocmé SD, Hallberg CK, Gill KS, Gleich
GJ, Tyring SK and Brysk MM: Effects of eosinophil granule proteins
on human corneal epithelial cell viability and morphology. Invest
Ophthalmol Vis Sci. 38:593–599. 1997.PubMed/NCBI
|
|
29
|
Maeda T, Kitazoe M, Tada H, et al: Growth
inhibition of mammalian cells by eosinophil cationic protein. Eur J
Biochem. 269:307–316. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Glimelius I, Rubin J, Fischer M, et al:
Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma
cell lines. Exp Hematol. 39:850–858. 2011. View Article : Google Scholar : PubMed/NCBI
|
